GERMANTOWN, Md. and BOSTON, June 30, 2016 (GLOBE NEWSWIRE) -- Intrexon Corporation (NYSE:XON), a leader in synthetic biology, and ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer
immunotherapies, today announced amendments to their Exclusive Channel Collaborations (ECCs) in the fields of oncology and
graft-versus-host-disease (GvHD) to improve alignment between both companies as ZIOPHARM broadens its pipeline and advances
multiple therapeutic programs into the clinic. The new structure is intended to facilitate increased investment in clinical
development by ZIOPHARM, including the execution of pivotal studies, across a number of cellular and gene therapies that it
employs.
Geno Germano, President of Intrexon, stated, “Intrexon is engaged in an array of collaborations with a wide
variety of partners. Our goal is always to work together to create value for both Intrexon shareholders and the shareholders
of our collaborators. As these relationships mature, business needs and conditions can evolve and create new
opportunities. In the case of ZIOPHARM and the tremendous prospects they possess with their cellular and gene based
approaches within oncology, both companies saw an opportunity to adjust the terms of our relationship for mutual benefit.”
Laurence Cooper, M.D., Ph.D., Chief Executive Officer of ZIOPHARM Oncology commented, “Intrexon and ZIOPHARM are
integral partners, working closely together to create innovative and more efficacious therapies for the treatment of cancer and
GvHD toward the ultimate goal of finding cures. By amending the terms of our collaborations, ZIOPHARM is better positioned to
advance its immunotherapy assets from first-in-human trials to eventual commercialization.”
Under the terms of the amendments:
- Operating profit rates payable to Intrexon from ZIOPHARM on products developed under its two existing collaborations will be
reduced from 50% to 20%. This reduction will not apply to any royalties or other payments made with respect to the
companies’ existing collaboration with Merck Serono, the biopharmaceutical business of Merck KGaA;
- Economics from any future sublicensing arrangements with potential third party collaborators will remain evenly split;
- In consideration of the amendments, ZIOPHARM will issue shares of a new class of preferred stock that would carry an initial
stated value of $120 million and a monthly dividend of 1% payable in additional preferred shares; and
- Upon the first approval of a product in the United States or upon certain fundamental transactions, such as a change of
control of ZIOPHARM, the preferred shares issued to Intrexon will be converted into ZIOPHARM common stock equal to the aggregate
stated value divided by the volume weighted average closing price of ZIOPHARM’s common stock over the 20 trading days ending on
the date that the product approval is announced or such transaction occurs.
Additional details of the agreement can be found in the companies’ filings with the U.S. Securities and Exchange
Commission.
Already with three active trials at leading institutions, two utilizing controlled gene therapy to express a
powerful anti-cancer effector in interleukin-12 and the other incorporating the innovative non-viral Sleeping Beauty gene
delivery system in chimeric antigen receptor T cell therapy (CAR-T) for advanced lymphoid malignancies, ZIOPHARM has positioned
itself to meaningfully expand its clinical programs through the remainder of 2016 and over the course of 2017. For the
current year these will include viral CAR-T for myeloid malignancies, natural killer (NK) cells for acute myeloid leukemia, and for
the first time a combination approach with Ad-RTS-hIL-12 used in conjunction with checkpoint inhibitors.
Additionally, ZIOPHARM and Intrexon continue to advance preclinical efforts leveraging the Sleeping
Beauty platform, the clinical-stage RheoSwitch® (RTS®), and cell manufacturing for the clinical applications of T cells
engineered to express CAR and TCR, as well as off-the-shelf approaches in NK and other cell types. Employing novel cell
engineering techniques and multigenic programs, the collaboration has progressed next-generation non-viral adoptive cellular
therapies based on designer cytokines and CARs under control of RheoSwitch® technology targeting both hematologic and
solid tumor malignancies. Many of these initiatives benefit from the companies’ ongoing collaboration with The University of Texas
MD Anderson Cancer Center, which facilitates a faster and more cost effective approach to move these promising treatments from the
bench to the clinic.
About Intrexon Corporation
Intrexon Corporation (NYSE:XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products
that improve the quality of life and the health of the planet. The Company's integrated technology suite provides its partners
across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control,
quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite
you to discover more at www.dna.com or follow us on Twitter at @Intrexon.
About ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell
technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer. The Company's
immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric
antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad
scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch
Therapeutic System® technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve
therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing
which are focused on hematologic and solid tumor malignancies.
Trademarks
Intrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates.
Other names may be trademarks of their respective owners.
Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based
upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations
for the development of our business. Although management believes that the plans and objectives reflected in or suggested by
these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future
results may be materially different from the plans, objectives and expectations expressed in this press release.
For more information, contact:
Intrexon Corporation
Investor Contact:
Christopher Basta
Vice President, Investor Relations
Tel: +1 (561) 410-7052
investors@intrexon.com
Corporate Contact:
Marie Rossi, Ph.D.
Senior Manager, Technical Communications
Tel: +1 (301) 556-9850
publicrelations@intrexon.com
ZIOPHARM:
Investor Contact:
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
Corporate Contact:
Lori Ann Occhiogrosso
ZIOPHARM Oncology, Inc.
617-259-1987
locchiogrosso@ziopharm.com
